Get the Stockscreener App
74.91
0.27%
0.205
Hologic Inc stock is traded at $74.91, with a volume of 2.22M.
It is up +0.27% in the last 24 hours and down -0.01% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$74.70
Open:
$74.81
24h Volume:
2.22M
Relative Volume:
0.79
Market Cap:
$16.72B
Revenue:
$4.04B
Net Income/Loss:
$557.10M
P/E Ratio:
31.08
EPS:
2.4102
Net Cash Flow:
$916.70M
1W Performance:
-0.04%
1M Performance:
-0.01%
6M Performance:
+11.98%
1Y Performance:
+14.44%
1-Day Range:
$74.81
$74.97
1-Week Range:
$74.50
$75.00
52-Week Range:
$51.90
$75.36
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX vs ISRG, BDX, RMD, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
74.91 | 16.68B | 4.04B | 557.10M | 916.70M | 2.4102 |
|
ISRG
Intuitive Surgical Inc
|
489.39 | 169.16B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
208.32 | 58.84B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
RMD
Resmed Inc
|
271.06 | 38.90B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
47.32 | 38.45B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ALC
Alcon Inc
|
78.52 | 38.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Argus | Buy → Hold |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-21-25 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic, Inc. (HOLX) Announces Shareholder Approval for Merger w - GuruFocus
Hologic Shareholders Approve Blackstone and TPG Buyout Deal - TipRanks
SA's Competition Commission approves proposed deal whereby Hopper parent intends to buy Hologic, without conditions - marketscreener.com
Hologic’s Aptima assay secures FDA approval for HPV primary screening - Medical Device Network
Hologic’s Aptima HPV assay receives FDA approval for primary screening By Investing.com - Investing.com Nigeria
Hologic Goes Global: Can International Expansion Offset China and Africa Headwinds? - Smartkarma
FDA Approves Hologic’s Aptima HPV Assay Primary Screening Option - Medical Product Outsourcing
Hologic receives FDA approval for Aptima® HPV assay primary screening option, expanding cervical health portfolio - marketscreener.com
Hologic Says US FDA Approves Aptima HPV Testing Assay - marketscreener.com
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health PortfolioHologic, Inc. - Hologic, Inc. - Investor Relations
United States Bone Densitometer Devices Market is expected - openPR.com
Robert Olstein's Strategic Moves: Exiting Hologic Inc with a -1.44% Impact - Yahoo Finance
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Hologic, Inc. (HOLX) is attracting investor attention: Here is what you should know - MSN
Hologic (HOLX) International Revenue Performance Explored - Yahoo Finance
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Hologic, Inc. (HOLX) Stock Analysis: Unpacking Growth Potential Amidst a Hold Rating Consensus - DirectorsTalk Interviews
Is Hologic Inc vulnerable to short sellersMarket Activity Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
(HOLX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Market Outlook: What are analysts price targets for Hologic Inc2025 Price Momentum & Weekly Top Performers Watchlists - baoquankhu1.vn
Hologic (HOLX) Q1 2026 Margin Compression Reinforces Cautious Community Narratives - Sahm
Evercore ISI Adjusts Hologic Price Target to $76 From $78, Maintains In Line Rating - marketscreener.com
Hologic Q1 comes up short of Street expectations ahead of sale to private equity - MassDevice
HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash - tradingview.com
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight - GuruFocus
Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Hologic (NASDAQ:HOLX) Misses Q4 CY2025 Revenue Estimates - Finviz
Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Setup Watch: Does Hologic Inc have a sustainable dividendForecast Cut & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Hologic: Fiscal First Quarter Earnings Overview - Bitget
Hologic (HOLX) Faces Legal Challenges Amid Merger and Product Re - GuruFocus
Hologic Fiscal Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Hologic: Fiscal Q1 Earnings Snapshot - kare11.com
Hologic misses Q1 earnings and revenue estimates, shares edge lower By Investing.com - Investing.com Nigeria
Hologic misses Q1 earnings and revenue estimates, shares edge lower - Investing.com
Hologic Announces Financial Results for First Quarter of Fiscal 2026 - TradingView
Hologic earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
HOLOGIC INC SEC 10-Q Report - TradingView
What you need to know ahead of Hologic's earnings release - MSN
Examining the Future: Hologic's Earnings Outlook - Benzinga
Why Analysts Are Rethinking The Story Behind Hologic (HOLX) After New Price Targets - Yahoo Finance
Hologic (HOLX) Q4 Earnings: What To Expect - Finviz
Hologic Earnings Report Q1 2026: Analyst Forecasts & Stock OutlookNews and Statistics - IndexBox
HOLOGIC Q1 2026 Earnings Preview: Recent $HOLX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Assessing Hologic (HOLX) Valuation As Shares Hover Near Analyst Fair Value Estimates - Yahoo Finance
Hologic stock hits 52-week high at 75.34 USD By Investing.com - Investing.com Canada
Hologic stock hits 52-week high at 75.34 USD - Investing.com
Hologic Faces Merger-Related Stockholder Suits, Issues Disclosures - TipRanks
Hologic (NASDAQ: HOLX) warns lower CVR value after Brevera recall in Blackstone–TPG buyout - stocktitan.net
Stay Ahead of the Game With Hologic (HOLX) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
The Truth About Hologic Inc: Why This ‘Boring’ Stock Could Be a Silent Game-Changer - AD HOC NEWS
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):